{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T17:04:02Z","timestamp":1794330242561,"version":"4.9.0"},"reference-count":220,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:00:00Z","timestamp":1784764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:00:00Z","timestamp":1784764800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Nephrol"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1038\/s41581-026-01103-y","type":"journal-article","created":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T10:10:40Z","timestamp":1784801440000},"page":"684-703","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Disease modification in lupus nephritis: towards a pathophysiology-based treatment paradigm"],"prefix":"10.1038","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3823-4702","authenticated-orcid":false,"given":"Mieke","family":"van Schaik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cees","family":"van Kooten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8077-8394","authenticated-orcid":false,"given":"Laurent","family":"Arnaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9752-9941","authenticated-orcid":false,"given":"Annette","family":"Bruchfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5830-9663","authenticated-orcid":false,"given":"Fernando","family":"Caravaca-Font\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gema M.","family":"Fernandez Juarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Floege","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1609-3857","authenticated-orcid":false,"given":"Ana","family":"Malvar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0362-8154","authenticated-orcid":false,"given":"Safak","family":"Mirioglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Moran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4875-5395","authenticated-orcid":false,"given":"Ioannis","family":"Parodis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7582-8476","authenticated-orcid":false,"given":"Luis F.","family":"Quintana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5639-0210","authenticated-orcid":false,"given":"Brad H.","family":"Rovin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5990-494X","authenticated-orcid":false,"given":"Stefanie","family":"Steiger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2291-1692","authenticated-orcid":false,"given":"Kate","family":"Stevens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2945-2946","authenticated-orcid":false,"given":"Andreas","family":"Kronbichler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9920-2195","authenticated-orcid":false,"given":"Y. K. Onno","family":"Teng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2516-002X","authenticated-orcid":false,"given":"Eleni","family":"Frangou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the European Renal Association (ERA) Immunonephrology Working Group (IWG)","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,23]]},"reference":[{"key":"1103_CR1","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/s41584-023-00925-5","volume":"19","author":"CC Mok","year":"2023","unstructured":"Mok, C. C., Teng, Y. K. O., Saxena, R. & Tanaka, Y. Treatment of lupus nephritis: consensus, evidence and perspectives. Nat. Rev. Rheumatol. 19, 227\u2013238 (2023).","journal-title":"Nat. Rev. Rheumatol."},{"key":"1103_CR2","doi-asserted-by":"publisher","first-page":"i4","DOI":"10.1093\/rheumatology\/keac610","volume":"62","author":"MRW Barber","year":"2023","unstructured":"Barber, M. R. W., Falasinnu, T., Ramsey-Goldman, R. & Clarke, A. E. The global epidemiology of SLE: narrowing the knowledge gaps. Rheumatology 62, i4\u2013i9 (2023).","journal-title":"Rheumatology"},{"key":"1103_CR3","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.3899\/jrheum.131137","volume":"41","author":"AJ Steiman","year":"2014","unstructured":"Steiman, A. J., Urowitz, M. B., Ibanez, D., Papneja, A. & Gladman, D. D. Prolonged clinical remission in patients with systemic lupus erythematosus. J. Rheumatol. 41, 1808\u20131816 (2014).","journal-title":"J. Rheumatol."},{"key":"1103_CR4","first-page":"1467","volume":"32","author":"MB Urowitz","year":"2005","unstructured":"Urowitz, M. B., Feletar, M., Bruce, I. N., Ibanez, D. & Gladman, D. D. Prolonged remission in systemic lupus erythematosus. J. Rheumatol. 32, 1467\u20131472 (2005).","journal-title":"J. Rheumatol."},{"key":"1103_CR5","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1136\/annrheumdis-2015-207347","volume":"74","author":"M Zen","year":"2015","unstructured":"Zen, M. et al. Prolonged remission in Caucasian patients with SLE: prevalence and outcomes. Ann. Rheum. Dis. 74, 2117\u20132122 (2015).","journal-title":"Ann. Rheum. Dis."},{"key":"1103_CR6","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1038\/s41584-024-01210-9","volume":"21","author":"M Stockfelt","year":"2025","unstructured":"Stockfelt, M., Teng, Y. K. O. & Vital, E. M. Opportunities and limitations of B cell depletion approaches in SLE. Nat. Rev. Rheumatol. 21, 111\u2013126 (2025).","journal-title":"Nat. Rev. Rheumatol."},{"key":"1103_CR7","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2023.09.002","volume":"105","author":"No author group","year":"2024","unstructured":"No author group Kidney Disease: Improving Global Outcomes Lupus Nephritis Work, G. KDIGO 2024 Clinical Practice Guideline for the management of LUPUS NEPHRITIS. Kidney Int. 105, S1\u2013S69 (2024).","journal-title":"Kidney Int."},{"key":"1103_CR8","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1002\/art.43212","volume":"77","author":"LR Sammaritano","year":"2025","unstructured":"Sammaritano, L. R. et al. 2024 American College of Rheumatology (ACR) guideline for the screening, treatment, and management of lupus nephritis. Arthritis Rheumatol. 77, 1115\u20131135 (2025).","journal-title":"Arthritis Rheumatol."},{"key":"1103_CR9","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.ard.2025.09.007","volume":"85","author":"A Fanouriakia","year":"2025","unstructured":"Fanouriakia, A. et al. EULAR recommendations for the management of systemic lupus erythematosus with kidney involvement: 2025 update. Ann. Rheum. Dis. 85, 75\u201390 (2025).","journal-title":"Ann. Rheum. Dis."},{"key":"1103_CR10","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1093\/ndt\/gfaf033","volume":"40","author":"YKO Teng","year":"2025","unstructured":"Teng, Y. K. O. et al. Disease-modifying anti-nephropathic drugs (DMANDs) \u2014 a definition proposed by the Immunonephrology Working Group (IWG) of the European Renal Association (ERA). Nephrol. Dial. Transplant. 40, 1243\u20131247 (2025).","journal-title":"Nephrol. Dial. Transplant."},{"key":"1103_CR11","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/nri2215","volume":"8","author":"H Kono","year":"2008","unstructured":"Kono, H. & Rock, K. L. How dying cells alert the immune system to danger. Nat. Rev. Immunol. 8, 279\u2013289 (2008).","journal-title":"Nat. Rev. Immunol."},{"key":"1103_CR12","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1038\/nrrheum.2010.46","volume":"6","author":"LE Munoz","year":"2010","unstructured":"Munoz, L. E., Lauber, K., Schiller, M., Manfredi, A. A. & Herrmann, M. The role of defective clearance of apoptotic cells in systemic autoimmunity. Nat. Rev. Rheumatol. 6, 280\u2013289 (2010).","journal-title":"Nat. Rev. Rheumatol."},{"key":"1103_CR13","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1002\/1521-4141(200206)32:6<1726::AID-IMMU1726>3.0.CO;2-R","volume":"32","author":"AJ Nauta","year":"2002","unstructured":"Nauta, A. J. et al. Direct binding of C1q to apoptotic cells and cell blebs induces complement activation. Eur. J. Immunol. 32, 1726\u20131736 (2002).","journal-title":"Eur. J. Immunol."},{"key":"1103_CR14","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1038\/gene.2011.39","volume":"12","author":"L Schejbel","year":"2011","unstructured":"Schejbel, L. et al. Molecular basis of hereditary C1q deficiency-revisited: identification of several novel disease-causing mutations. Genes Immun. 12, 626\u2013634 (2011).","journal-title":"Genes Immun."},{"key":"1103_CR15","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/S0065-2776(01)76021-X","volume":"76","author":"MC Pickering","year":"2000","unstructured":"Pickering, M. C., Botto, M., Taylor, P. R., Lachmann, P. J. & Walport, M. J. Systemic lupus erythematosus, complement deficiency, and apoptosis. Adv. Immunol. 76, 227\u2013324 (2000).","journal-title":"Adv. Immunol."},{"key":"1103_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2016.00055","volume":"7","author":"AC Macedo","year":"2016","unstructured":"Macedo, A. C. & Isaac, L. Systemic lupus erythematosus and deficiencies of early components of the complement classical pathway. Front. Immunol. 7, 55 (2016).","journal-title":"Front. Immunol."},{"key":"1103_CR17","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1002\/art.42941","volume":"76","author":"A Fava","year":"2024","unstructured":"Fava, A. et al. Association of autoantibody concentrations and trajectories with lupus nephritis histologic features and treatment response. Arthritis Rheumatol. 76, 1611\u20131622 (2024).","journal-title":"Arthritis Rheumatol."},{"key":"1103_CR18","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1093\/ndt\/gfad266","volume":"39","author":"D Maier-Begandt","year":"2024","unstructured":"Maier-Begandt, D. et al. Neutrophils-biology and diversity. Nephrol. Dial. Transplant. 39, 1551\u20131564 (2024).","journal-title":"Nephrol. Dial. Transplant."},{"key":"1103_CR19","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3001201","volume":"3","author":"GS Garcia-Romo","year":"2011","unstructured":"Garcia-Romo, G. S. et al. Netting neutrophils are major inducers of type I IFN production in pediatric systemic lupus erythematosus. Sci. Transl. Med. 3, 73ra20 (2011).","journal-title":"Sci. Transl. Med."},{"key":"1103_CR20","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3001180","volume":"3","author":"R Lande","year":"2011","unstructured":"Lande, R. et al. Neutrophils activate plasmacytoid dendritic cells by releasing self-DNA-peptide complexes in systemic lupus erythematosus. Sci. Transl. Med. 3, 73ra19 (2011).","journal-title":"Sci. Transl. Med."},{"key":"1103_CR21","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1038\/nature06116","volume":"449","author":"R Lande","year":"2007","unstructured":"Lande, R. et al. Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature 449, 564\u2013569 (2007).","journal-title":"Nature"},{"key":"1103_CR22","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1084\/jem.20090480","volume":"206","author":"D Ganguly","year":"2009","unstructured":"Ganguly, D. et al. Self-RNA-antimicrobial peptide complexes activate human dendritic cells through TLR7 and TLR8. J. Exp. Med. 206, 1983\u20131994 (2009).","journal-title":"J. Exp. Med."},{"key":"1103_CR23","doi-asserted-by":"publisher","first-page":"9813","DOI":"10.1073\/pnas.0909927107","volume":"107","author":"A Hakkim","year":"2010","unstructured":"Hakkim, A. et al. Impairment of neutrophil extracellular trap degradation is associated with lupus nephritis. Proc. Natl Acad. Sci. USA 107, 9813\u20139818 (2010).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1103_CR24","doi-asserted-by":"publisher","first-page":"3522","DOI":"10.4049\/jimmunol.1102404","volume":"188","author":"J Leffler","year":"2012","unstructured":"Leffler, J. et al. Neutrophil extracellular traps that are not degraded in systemic lupus erythematosus activate complement exacerbating the disease. J. Immunol. 188, 3522\u20133531 (2012).","journal-title":"J. Immunol."},{"key":"1103_CR25","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1002\/art.39417","volume":"68","author":"J Dieker","year":"2016","unstructured":"Dieker, J. et al. Circulating apoptotic microparticles in systemic lupus erythematosus patients drive the activation of dendritic cell subsets and prime neutrophils for NETosis. Arthritis Rheumatol. 68, 462\u2013472 (2016).","journal-title":"Arthritis Rheumatol."},{"key":"1103_CR26","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1038\/s41577-022-00787-0","volume":"23","author":"G Wigerblad","year":"2023","unstructured":"Wigerblad, G. & Kaplan, M. J. Neutrophil extracellular traps in systemic autoimmune and autoinflammatory diseases. Nat. Rev. Immunol. 23, 274\u2013288 (2023).","journal-title":"Nat. Rev. Immunol."},{"key":"1103_CR27","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1136\/annrheumdis-2018-213181","volume":"78","author":"E Frangou","year":"2019","unstructured":"Frangou, E. et al. REDD1\/autophagy pathway promotes thromboinflammation and fibrosis in human systemic lupus erythematosus (SLE) through NETs decorated with tissue factor (TF) and interleukin-17A (IL-17A). Ann. Rheum. Dis. 78, 238\u2013248 (2019).","journal-title":"Ann. Rheum. Dis."},{"key":"1103_CR28","first-page":"644","volume":"56","author":"J Lee","year":"2017","unstructured":"Lee, J. et al. Nicotine drives neutrophil extracellular traps formation and accelerates collagen-induced arthritis. Rheumatology 56, 644\u2013653 (2017).","journal-title":"Rheumatology"},{"key":"1103_CR29","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/nri2975","volume":"11","author":"AP West","year":"2011","unstructured":"West, A. P., Shadel, G. S. & Ghosh, S. Mitochondria in innate immune responses. Nat. Rev. Immunol. 11, 389\u2013402 (2011).","journal-title":"Nat. Rev. Immunol."},{"key":"1103_CR30","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1189\/jlb.0703328","volume":"75","author":"LV Collins","year":"2004","unstructured":"Collins, L. V., Hajizadeh, S., Holme, E., Jonsson, I. M. & Tarkowski, A. Endogenously oxidized mitochondrial DNA induces in vivo and in vitro inflammatory responses. J. Leukoc. Biol. 75, 995\u20131000 (2004).","journal-title":"J. Leukoc. Biol."},{"key":"1103_CR31","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/nature08780","volume":"464","author":"Q Zhang","year":"2010","unstructured":"Zhang, Q. et al. Circulating mitochondrial DAMPs cause inflammatory responses to injury. Nature 464, 104\u2013107 (2010).","journal-title":"Nature"},{"key":"1103_CR32","doi-asserted-by":"publisher","first-page":"538","DOI":"10.4049\/jimmunol.1100450","volume":"187","author":"E Villanueva","year":"2011","unstructured":"Villanueva, E. et al. Netting neutrophils induce endothelial damage, infiltrate tissues, and expose immunostimulatory molecules in systemic lupus erythematosus. J. Immunol. 187, 538\u2013552 (2011).","journal-title":"J. Immunol."},{"key":"1103_CR33","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1016\/j.autrev.2019.06.011","volume":"18","author":"E Frangou","year":"2019","unstructured":"Frangou, E., Vassilopoulos, D., Boletis, J. & Boumpas, D. T. An emerging role of neutrophils and NETosis in chronic inflammation and fibrosis in systemic lupus erythematosus (SLE) and ANCA-associated vasculitides (AAV): implications for the pathogenesis and treatment. Autoimmun. Rev. 18, 751\u2013760 (2019).","journal-title":"Autoimmun. Rev."},{"key":"1103_CR34","doi-asserted-by":"publisher","first-page":"2763","DOI":"10.2169\/internalmedicine.53.2570","volume":"53","author":"S Zhang","year":"2014","unstructured":"Zhang, S. et al. Elevated plasma cfDNA may be associated with active lupus nephritis and partially attributed to abnormal regulation of neutrophil extracellular traps (NETs) in patients with systemic lupus erythematosus. Intern. Med. 53, 2763\u20132771 (2014).","journal-title":"Intern. Med."},{"key":"1103_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-37083-x","volume":"14","author":"E Gomez-Banuelos","year":"2023","unstructured":"Gomez-Banuelos, E. et al. Affinity maturation generates pathogenic antibodies with dual reactivity to DNase1L3 and dsDNA in systemic lupus erythematosus. Nat. Commun. 14, 1388 (2023).","journal-title":"Nat. Commun."},{"key":"1103_CR36","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/35047580","volume":"2","author":"P Avner","year":"2001","unstructured":"Avner, P. & Heard, E. X-chromosome inactivation: counting, choice and initiation. Nat. Rev. Genet. 2, 59\u201367 (2001).","journal-title":"Nat. Rev. Genet."},{"key":"1103_CR37","doi-asserted-by":"crossref","first-page":"E2029","DOI":"10.1073\/pnas.1520487113","volume":"113","author":"J Wang","year":"2016","unstructured":"Wang, J. et al. Unusual maintenance of X chromosome inactivation predisposes female lymphocytes for increased expression from the inactive X. Proc. Natl Acad. Sci. USA 113, E2029\u2013E2038 (2016).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1103_CR38","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.126751","volume":"4","author":"CM Syrett","year":"2019","unstructured":"Syrett, C. M. et al. Altered X-chromosome inactivation in T cells may promote sex-biased autoimmune diseases. JCI Insight 4, e126751 (2019).","journal-title":"JCI Insight"},{"key":"1103_CR39","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.immuni.2006.07.013","volume":"25","author":"SR Christensen","year":"2006","unstructured":"Christensen, S. R. et al. Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus. Immunity 25, 417\u2013428 (2006).","journal-title":"Immunity"},{"key":"1103_CR40","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/s41586-022-04642-z","volume":"605","author":"GJ Brown","year":"2022","unstructured":"Brown, G. J. et al. TLR7 gain-of-function genetic variation causes human lupus. Nature 605, 349\u2013356 (2022).","journal-title":"Nature"},{"key":"1103_CR41","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.aap8855","volume":"3","author":"M Souyris","year":"2018","unstructured":"Souyris, M. et al. TLR7 escapes X chromosome inactivation in immune cells. Sci. Immunol. 3, eaap8855 (2018).","journal-title":"Sci. Immunol."},{"key":"1103_CR42","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1038\/nrrheum.2010.176","volume":"6","author":"Y Deng","year":"2010","unstructured":"Deng, Y. & Tsao, B. P. Genetic susceptibility to systemic lupus erythematosus in the genomic era. Nat. Rev. Rheumatol. 6, 683\u2013692 (2010).","journal-title":"Nat. Rev. Rheumatol."},{"key":"1103_CR43","doi-asserted-by":"publisher","first-page":"178","DOI":"10.7326\/0003-4819-115-3-178","volume":"115","author":"LE Ronnblom","year":"1991","unstructured":"Ronnblom, L. E., Alm, G. V. & Oberg, K. E. Autoimmunity after alpha-interferon therapy for malignant carcinoid tumors. Ann. Intern. Med. 115, 178\u2013183 (1991).","journal-title":"Ann. Intern. Med."},{"key":"1103_CR44","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1038\/nri2358","volume":"8","author":"M Gilliet","year":"2008","unstructured":"Gilliet, M., Cao, W. & Liu, Y. J. Plasmacytoid dendritic cells: sensing nucleic acids in viral infection and autoimmune diseases. Nat. Rev. Immunol. 8, 594\u2013606 (2008).","journal-title":"Nat. Rev. Immunol."},{"key":"1103_CR45","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1038\/s41590-019-0466-2","volume":"20","author":"FJ Barrat","year":"2019","unstructured":"Barrat, F. J., Crow, M. K. & Ivashkiv, L. B. Interferon target-gene expression and epigenomic signatures in health and disease. Nat. Immunol. 20, 1574\u20131583 (2019).","journal-title":"Nat. Immunol."},{"key":"1103_CR46","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.rdc.2021.04.006","volume":"47","author":"SP Canny","year":"2021","unstructured":"Canny, S. P. & Jackson, S. W. B cells in systemic lupus erythematosus: from disease mechanisms to targeted therapies. Rheum. Dis. Clin. North Am. 47, 395\u2013413 (2021).","journal-title":"Rheum. Dis. Clin. North Am."},{"key":"1103_CR47","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1056\/NEJMoa1610528","volume":"376","author":"M Steri","year":"2017","unstructured":"Steri, M. et al. Overexpression of the cytokine BAFF and autoimmunity risk. N. Engl. J. Med. 376, 1615\u20131626 (2017).","journal-title":"N. Engl. J. Med."},{"key":"1103_CR48","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1146\/annurev.immunol.21.120601.141152","volume":"21","author":"F Mackay","year":"2003","unstructured":"Mackay, F., Schneider, P., Rennert, P. & Browning, J. BAFF and APRIL: a tutorial on B cell survival. Annu. Rev. Immunol. 21, 231\u2013264 (2003).","journal-title":"Annu. Rev. Immunol."},{"key":"1103_CR49","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.clim.2017.07.004","volume":"183","author":"B Xu","year":"2017","unstructured":"Xu, B. et al. The ratio of circulating follicular T helper cell to follicular T regulatory cell is correlated with disease activity in systemic lupus erythematosus. Clin. Immunol. 183, 46\u201353 (2017).","journal-title":"Clin. Immunol."},{"key":"1103_CR50","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1172\/JCI200421075","volume":"114","author":"LA Trouw","year":"2004","unstructured":"Trouw, L. A. et al. Anti-C1q autoantibodies deposit in glomeruli but are only pathogenic in combination with glomerular C1q-containing immune complexes. J. Clin. Invest. 114, 679\u2013688 (2004).","journal-title":"J. Clin. Invest."},{"key":"1103_CR51","doi-asserted-by":"publisher","first-page":"373","DOI":"10.3109\/08916934.2010.541170","volume":"44","author":"JE Mjelle","year":"2011","unstructured":"Mjelle, J. E., Rekvig, O. P., Van Der Vlag, J. & Fenton, K. A. Nephritogenic antibodies bind in glomeruli through interaction with exposed chromatin fragments and not with renal cross-reactive antigens. Autoimmunity 44, 373\u2013383 (2011).","journal-title":"Autoimmunity"},{"key":"1103_CR52","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.2353\/ajpath.2006.051329","volume":"168","author":"M Kalaaji","year":"2006","unstructured":"Kalaaji, M., Mortensen, E., Jorgensen, L., Olsen, R. & Rekvig, O. P. Nephritogenic lupus antibodies recognize glomerular basement membrane-associated chromatin fragments released from apoptotic intraglomerular cells. Am. J. Pathol. 168, 1779\u20131792 (2006).","journal-title":"Am. J. Pathol."},{"key":"1103_CR53","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s00428-003-0827-x","volume":"443","author":"H Makino","year":"2003","unstructured":"Makino, H. et al. Glomerular cell apoptosis in human lupus nephritis. Virchows Arch. 443, 67\u201377 (2003).","journal-title":"Virchows Arch."},{"key":"1103_CR54","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1038\/sj.ki.5002133","volume":"71","author":"M Kalaaji","year":"2007","unstructured":"Kalaaji, M. et al. Glomerular apoptotic nucleosomes are central target structures for nephritogenic antibodies in human SLE nephritis. Kidney Int. 71, 664\u2013672 (2007).","journal-title":"Kidney Int."},{"key":"1103_CR55","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01667","volume":"10","author":"X Wang","year":"2019","unstructured":"Wang, X. & Xia, Y. Anti-double stranded DNA antibodies: origin, pathogenicity, and targeted therapies. Front. Immunol. 10, 1667 (2019).","journal-title":"Front. Immunol."},{"key":"1103_CR56","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/s41577-022-00816-y","volume":"23","author":"HJ Anders","year":"2023","unstructured":"Anders, H. J., Kitching, A. R., Leung, N. & Romagnani, P. Glomerulonephritis: immunopathogenesis and immunotherapy. Nat. Rev. Immunol. 23, 453\u2013471 (2023).","journal-title":"Nat. Rev. Immunol."},{"key":"1103_CR57","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/j.kint.2017.11.023","volume":"93","author":"IM Bajema","year":"2018","unstructured":"Bajema, I. M. et al. Revision of the International Society of Nephrology\/Renal Pathology Society classification for lupus nephritis: clarification of definitions, and modified National Institutes of Health activity and chronicity indices. Kidney Int. 93, 789\u2013796 (2018).","journal-title":"Kidney Int."},{"key":"1103_CR58","doi-asserted-by":"publisher","first-page":"3413","DOI":"10.1172\/JCI97879","volume":"128","author":"A Chen","year":"2018","unstructured":"Chen, A. et al. Bowman\u2019s capsule provides a protective niche for podocytes from cytotoxic CD8+ T cells. J. Clin. Invest. 128, 3413\u20133424 (2018).","journal-title":"J. Clin. Invest."},{"key":"1103_CR59","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8091340","volume":"8","author":"H Sakhi","year":"2019","unstructured":"Sakhi, H. et al. Podocyte injury in lupus nephritis. J. Clin. Med. 8, 1340 (2019).","journal-title":"J. Clin. Med."},{"key":"1103_CR60","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.jaut.2015.01.008","volume":"58","author":"S Yung","year":"2015","unstructured":"Yung, S. et al. Anti-dsDNA antibody induces soluble fibronectin secretion by proximal renal tubular epithelial cells and downstream increase of TGF-\u03b21 and collagen synthesis. J. Autoimmun. 58, 111\u2013122 (2015).","journal-title":"J. Autoimmun."},{"key":"1103_CR61","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/S0025-6196(24)00526-3","volume":"24","author":"PS Hench","year":"1949","unstructured":"Hench, P. S. et al. The effect of a hormone of the adrenal cortex (17-hydroxy-11-dehydrocorticosterone; compound E) and of pituitary adrenocorticotropic hormone on rheumatoid arthritis. Proc. Staff Meet. Mayo Clin. 24, 181\u2013197 (1949).","journal-title":"Proc. Staff Meet. Mayo Clin."},{"key":"1103_CR62","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1136\/annrheumdis-2013-203205","volume":"72","author":"FA Houssiau","year":"2013","unstructured":"Houssiau, F. A. & Isenberg, D. Towards treating lupus nephritis without oral steroids: a dream-come-true? Ann. Rheum. Dis. 72, 1271\u20131272 (2013).","journal-title":"Ann. Rheum. Dis."},{"key":"1103_CR63","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1681\/ASN.0000000000000365","volume":"35","author":"E Frangou","year":"2024","unstructured":"Frangou, E. et al. Immunosuppression withdrawal in patients with lupus nephritis: when, how, and for whom will it be safe? J. Am. Soc. Nephrol. 35, 955\u2013958 (2024).","journal-title":"J. Am. Soc. Nephrol."},{"key":"1103_CR64","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1136\/annrheumdis-2019-216303","volume":"79","author":"A Mathian","year":"2020","unstructured":"Mathian, A. et al. Withdrawal of low-dose prednisone in SLE patients with a clinically quiescent disease for more than 1 year: a randomised clinical trial. Ann. Rheum. Dis. 79, 339\u2013346 (2020).","journal-title":"Ann. Rheum. Dis."},{"key":"1103_CR65","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2021-000603","volume":"9","author":"L Ji","year":"2022","unstructured":"Ji, L., Xie, W., Fasano, S. & Zhang, Z. Risk factors of flare in patients with systemic lupus erythematosus after glucocorticoids withdrawal. A systemic review and meta-analysis. Lupus Sci. Med. 9, e000603 (2022).","journal-title":"Lupus Sci. Med."},{"key":"1103_CR66","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13206049","volume":"13","author":"G Ruiz-Irastorza","year":"2024","unstructured":"Ruiz-Irastorza, G. et al. No effect of low-dose glucocorticoid maintenance therapy on damage in SLE patients in prolonged remission: a propensity score analysis of the longitudinal Lupus-Cruces-Bordeaux inception cohort. J. Clin. Med. 13, 6049 (2024).","journal-title":"J. Clin. Med."},{"key":"1103_CR67","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1136\/annrheumdis-2012-202844","volume":"72","author":"MB Condon","year":"2013","unstructured":"Condon, M. B. et al. Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids. Ann. Rheum. Dis. 72, 1280\u20131286 (2013).","journal-title":"Ann. Rheum. Dis."},{"key":"1103_CR68","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2024-001428","volume":"12","author":"L Arnaud","year":"2025","unstructured":"Arnaud, L. et al. Real-world oral glucocorticoid use in SLE: a nation-wide population-based study using the French medico-administrative (SNDS) claim database. Lupus Sci. Med. 12, e001428 (2025).","journal-title":"Lupus Sci. Med."},{"key":"1103_CR69","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1056\/NEJM198603063141004","volume":"314","author":"HA Austin 3rd","year":"1986","unstructured":"Austin, H. A. 3rd et al. Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N. Engl. J. Med. 314, 614\u2013619 (1986).","journal-title":"N. Engl. J. Med."},{"key":"1103_CR70","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7326\/0003-4819-99-1-1","volume":"99","author":"S Carette","year":"1983","unstructured":"Carette, S. et al. Controlled studies of oral immunosuppressive drugs in lupus nephritis. A long-term follow-up. Ann. Intern. Med. 99, 1\u20138 (1983).","journal-title":"Ann. Intern. Med."},{"key":"1103_CR71","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1038\/nrclinonc.2009.146","volume":"6","author":"A Emadi","year":"2009","unstructured":"Emadi, A., Jones, R. J. & Brodsky, R. A. Cyclophosphamide and cancer: golden anniversary. Nat. Rev. Clin. Oncol. 6, 638\u2013647 (2009).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1103_CR72","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1038\/s41584-020-0374-8","volume":"16","author":"JCA Broen","year":"2020","unstructured":"Broen, J. C. A. & van Laar, J. M. Mycophenolate mofetil, azathioprine and tacrolimus: mechanisms in rheumatology. Nat. Rev. Rheumatol. 16, 167\u2013178 (2020).","journal-title":"Nat. Rev. Rheumatol."},{"key":"1103_CR73","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/0140-6736(92)92292-N","volume":"340","author":"DT Boumpas","year":"1992","unstructured":"Boumpas, D. T. et al. Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 340, 741\u2013745 (1992).","journal-title":"Lancet"},{"key":"1103_CR74","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa043731","volume":"353","author":"EM Ginzler","year":"2005","unstructured":"Ginzler, E. M. et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N. Engl. J. Med. 353, 2219\u20132228 (2005).","journal-title":"N. Engl. J. Med."},{"key":"1103_CR75","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1681\/ASN.2008101028","volume":"20","author":"GB Appel","year":"2009","unstructured":"Appel, G. B. et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J. Am. Soc. Nephrol. 20, 1103\u20131112 (2009).","journal-title":"J. Am. Soc. Nephrol."},{"key":"1103_CR76","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1053\/j.ajkd.2016.12.008","volume":"70","author":"SC Palmer","year":"2017","unstructured":"Palmer, S. C. et al. Induction and maintenance immunosuppression treatment of proliferative lupus nephritis: a network meta-analysis of randomized trials. Am. J. Kidney Dis. 70, 324\u2013336 (2017).","journal-title":"Am. J. Kidney Dis."},{"key":"1103_CR77","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.1056\/NEJMoa1014460","volume":"365","author":"MA Dooley","year":"2011","unstructured":"Dooley, M. A. et al. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N. Engl. J. Med. 365, 1886\u20131895 (2011).","journal-title":"N. Engl. J. Med."},{"key":"1103_CR78","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1056\/NEJM200010193431604","volume":"343","author":"TM Chan","year":"2000","unstructured":"Chan, T. M. et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N. Engl. J. Med. 343, 1156\u20131162 (2000).","journal-title":"N. Engl. J. Med."},{"key":"1103_CR79","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1136\/annrheumdis-2014-206897","volume":"75","author":"F Tamirou","year":"2016","unstructured":"Tamirou, F. et al. Long-term follow-up of the MAINTAIN Nephritis Trial, comparing azathioprine and mycophenolate mofetil as maintenance therapy of lupus nephritis. Ann. Rheum. Dis. 75, 526\u2013531 (2016).","journal-title":"Ann. Rheum. Dis."},{"key":"1103_CR80","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01184","volume":"9","author":"EF Wallin","year":"2018","unstructured":"Wallin, E. F., Hill, D. L., Linterman, M. A. & Wood, K. J. The calcineurin inhibitor tacrolimus specifically suppresses human T follicular helper cells. Front. Immunol. 9, 1184 (2018).","journal-title":"Front. Immunol."},{"key":"1103_CR81","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0132724","volume":"10","author":"R Liao","year":"2015","unstructured":"Liao, R. et al. Tacrolimus protects podocytes from injury in lupus nephritis partly by stabilizing the cytoskeleton and inhibiting podocyte apoptosis. PLoS One 10, e0132724 (2015).","journal-title":"PLoS One"},{"key":"1103_CR82","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1002\/art.39026","volume":"67","author":"M Dall\u2019Era","year":"2015","unstructured":"Dall\u2019Era, M. et al. Predictors of long-term renal outcome in lupus nephritis trials: lessons learned from the Euro-Lupus Nephritis cohort. Arthritis Rheumatol. 67, 1305\u20131313 (2015).","journal-title":"Arthritis Rheumatol."},{"key":"1103_CR83","doi-asserted-by":"publisher","first-page":"46","DOI":"10.2215\/CJN.03280807","volume":"3","author":"YE Chen","year":"2008","unstructured":"Chen, Y. E. et al. Value of a complete or partial remission in severe lupus nephritis. Clin. J. Am. Soc. Nephrol. 3, 46\u201353 (2008).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"1103_CR84","doi-asserted-by":"publisher","first-page":"671","DOI":"10.3899\/jrheum.161554","volume":"45","author":"JE Davidson","year":"2018","unstructured":"Davidson, J. E. et al. Renal remission status and longterm renal survival in patients with lupus nephritis: a retrospective cohort analysis. J. Rheumatol. 45, 671\u2013677 (2018).","journal-title":"J. Rheumatol."},{"key":"1103_CR85","doi-asserted-by":"publisher","first-page":"2070","DOI":"10.1016\/S0140-6736(21)00578-X","volume":"397","author":"BH Rovin","year":"2021","unstructured":"Rovin, B. H. et al. Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 397, 2070\u20132080 (2021).","journal-title":"Lancet"},{"key":"1103_CR86","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1002\/art.42657","volume":"76","author":"A Saxena","year":"2024","unstructured":"Saxena, A. et al. Safety and efficacy of long-term voclosporin treatment for lupus nephritis in the phase 3 AURORA 2 clinical trial. Arthritis Rheumatol. 76, 59\u201367 (2024).","journal-title":"Arthritis Rheumatol."},{"key":"1103_CR87","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1002\/art.43209","volume":"77","author":"BH Rovin","year":"2025","unstructured":"Rovin, B. H. et al. Effect of long-term voclosporin treatment on renal histology in patients with active lupus nephritis with repeat renal biopsies. Arthritis Rheumatol. 77, 1387\u20131393 (2025).","journal-title":"Arthritis Rheumatol."},{"key":"1103_CR88","doi-asserted-by":"publisher","DOI":"10.3390\/cells12202440","volume":"12","author":"A Kale","year":"2023","unstructured":"Kale, A., Shelke, V., Lei, Y., Gaikwad, A. B. & Anders, H. J. Voclosporin: unique chemistry, pharmacology and toxicity profile, and possible options for implementation into the management of lupus nephritis. Cells 12, 2440 (2023).","journal-title":"Cells"},{"key":"1103_CR89","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1177\/0961203314540353","volume":"23","author":"P Webster","year":"2014","unstructured":"Webster, P. et al. Tacrolimus is an effective treatment for lupus nephritis in pregnancy. Lupus 23, 1192\u20131196 (2014).","journal-title":"Lupus"},{"key":"1103_CR90","doi-asserted-by":"publisher","first-page":"2048","DOI":"10.1093\/ndt\/gfae113","volume":"39","author":"M van Schaik","year":"2024","unstructured":"van Schaik, M. et al. Long-term renal and cardiovascular risks of tacrolimus in patients with lupus nephritis. Nephrol. Dial. Transplant. 39, 2048\u20132057 (2024).","journal-title":"Nephrol. Dial. Transplant."},{"key":"1103_CR91","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1056\/NEJMoa2001180","volume":"383","author":"R Furie","year":"2020","unstructured":"Furie, R. et al. Two-year, randomized, controlled trial of belimumab in lupus nephritis. N. Engl. J. Med. 383, 1117\u20131128 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1103_CR92","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1136\/annrheumdis-2021-220920","volume":"81","author":"RA Furie","year":"2021","unstructured":"Furie, R. A. et al. B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial. Ann. Rheum. Dis. 81, 100\u2013107 (2021).","journal-title":"Ann. Rheum. Dis."},{"key":"1103_CR93","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1038\/nri3190","volume":"12","author":"DJ Rawlings","year":"2012","unstructured":"Rawlings, D. J., Schwartz, M. A., Jackson, S. W. & Meyer-Bahlburg, A. Integration of B cell responses through Toll-like receptors and antigen receptors. Nat. Rev. Immunol. 12, 282\u2013294 (2012).","journal-title":"Nat. Rev. Immunol."},{"key":"1103_CR94","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1002\/eji.202149361","volume":"52","author":"C Cenac","year":"2022","unstructured":"Cenac, C., Ducatez, M. F. & Guery, J. C. Hydroxychloroquine inhibits proteolytic processing of endogenous TLR7 protein in human primary plasmacytoid dendritic cells. Eur. J. Immunol. 52, 54\u201361 (2022).","journal-title":"Eur. J. Immunol."},{"key":"1103_CR95","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1093\/ndt\/gfae280","volume":"40","author":"M Pappa","year":"2025","unstructured":"Pappa, M., Boumpas, D. T. & Fanouriakis, A. Hydroxychloroquine for all patients with lupus nephritis: yes. Nephrol. Dial. Transplant. 40, 610\u2013613 (2025).","journal-title":"Nephrol. Dial. Transplant."},{"key":"1103_CR96","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.2215\/CJN.04830421","volume":"16","author":"G Moroni","year":"2021","unstructured":"Moroni, G., Frontini, G. & Ponticelli, C. When and how is it possible to stop therapy in patients with lupus nephritis: a narrative review. Clin. J. Am. Soc. Nephrol. 16, 1909\u20131917 (2021).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"1103_CR97","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1080\/14740338.2017.1269168","volume":"16","author":"C Ponticelli","year":"2017","unstructured":"Ponticelli, C. & Moroni, G. Hydroxychloroquine in systemic lupus erythematosus (SLE). Expert Opin. Drug Saf. 16, 411\u2013419 (2017).","journal-title":"Expert Opin. Drug Saf."},{"key":"1103_CR98","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2024-004701","volume":"10","author":"Y Tanaka","year":"2024","unstructured":"Tanaka, Y. et al. Safety, pharmacokinetics, biomarker response and efficacy of E6742: a dual antagonist of Toll-like receptors 7 and 8, in a first in patient, randomised, double-blind, phase I\/II study in systemic lupus erythematosus. RMD Open 10, e004701 (2024).","journal-title":"RMD Open"},{"key":"1103_CR99","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1046\/j.1365-2249.1999.00772.x","volume":"115","author":"H Vallin","year":"1999","unstructured":"Vallin, H., Blomberg, S., Alm, G. V., Cederblad, B. & Ronnblom, L. Patients with systemic lupus erythematosus (SLE) have a circulating inducer of interferon-alpha (IFN-\u03b1) production acting on leucocytes resembling immature dendritic cells. Clin. Exp. Immunol. 115, 196\u2013202 (1999).","journal-title":"Clin. Exp. Immunol."},{"key":"1103_CR100","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1084\/jem.20050914","volume":"202","author":"FJ Barrat","year":"2005","unstructured":"Barrat, F. J. et al. Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus. J. Exp. Med. 202, 1131\u20131139 (2005).","journal-title":"J. Exp. Med."},{"key":"1103_CR101","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1002\/art.20254","volume":"50","author":"T Lovgren","year":"2004","unstructured":"Lovgren, T., Eloranta, M. L., Bave, U., Alm, G. V. & Ronnblom, L. Induction of interferon-alpha production in plasmacytoid dendritic cells by immune complexes containing nucleic acid released by necrotic or late apoptotic cells and lupus IgG. Arthritis Rheum. 50, 1861\u20131872 (2004).","journal-title":"Arthritis Rheum."},{"key":"1103_CR102","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/ni1457","volume":"8","author":"J Tian","year":"2007","unstructured":"Tian, J. et al. Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat. Immunol. 8, 487\u2013496 (2007).","journal-title":"Nat. Immunol."},{"key":"1103_CR103","doi-asserted-by":"publisher","first-page":"e208","DOI":"10.1016\/S2665-9913(19)30076-1","volume":"1","author":"RA Furie","year":"2019","unstructured":"Furie, R. A. et al. Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial. Lancet Rheumatol. 1, e208\u2013e219 (2019).","journal-title":"Lancet Rheumatol."},{"key":"1103_CR104","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1056\/NEJMoa1912196","volume":"382","author":"EF Morand","year":"2020","unstructured":"Morand, E. F. et al. Trial of anifrolumab in active systemic lupus erythematosus. N. Engl. J. Med. 382, 211\u2013221 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1103_CR105","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1002\/art.42392","volume":"75","author":"KC Kalunian","year":"2023","unstructured":"Kalunian, K. C. et al. A randomized, placebo-controlled phase III extension trial of the long-term safety and tolerability of anifrolumab in active systemic lupus erythematosus. Arthritis Rheumatol. 75, 253\u2013265 (2023).","journal-title":"Arthritis Rheumatol."},{"key":"1103_CR106","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1093\/rheumatology\/keac491","volume":"62","author":"IN Bruce","year":"2023","unstructured":"Bruce, I. N. et al. Sustained glucocorticoid tapering in the phase 3 trials of anifrolumab: a post hoc analysis of the TULIP-1 and TULIP-2 trials. Rheumatology 62, 1526\u20131534 (2023).","journal-title":"Rheumatology"},{"key":"1103_CR107","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1136\/annrheumdis-2021-221425","volume":"81","author":"EM Vital","year":"2022","unstructured":"Vital, E. M. et al. Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials. Ann. Rheum. Dis. 81, 951\u2013961 (2022).","journal-title":"Ann. Rheum. Dis."},{"key":"1103_CR108","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1136\/annrheumdis-2021-221478","volume":"81","author":"D Jayne","year":"2022","unstructured":"Jayne, D. et al. Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis. Ann. Rheum. Dis. 81, 496\u2013506 (2022).","journal-title":"Ann. Rheum. Dis."},{"key":"1103_CR109","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2023-000910","volume":"10","author":"D Jayne","year":"2023","unstructured":"Jayne, D. et al. Anifrolumab in lupus nephritis: results from second-year extension of a randomised phase II trial. Lupus Sci. Med. 10, e000910 (2023).","journal-title":"Lupus Sci. Med."},{"key":"1103_CR110","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT05138133 (2026)."},{"key":"1103_CR111","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1016\/S0140-6736(22)02607-1","volume":"401","author":"EF Morand","year":"2023","unstructured":"Morand, E. F. et al. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-I). Lancet 401, 1001\u20131010 (2023).","journal-title":"Lancet"},{"key":"1103_CR112","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/S0140-6736(22)02546-6","volume":"401","author":"M Petri","year":"2023","unstructured":"Petri, M. et al. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II). Lancet 401, 1011\u20131019 (2023).","journal-title":"Lancet"},{"key":"1103_CR113","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2020-001490","volume":"6","author":"M Baker","year":"2020","unstructured":"Baker, M. et al. Phase II, randomised, double-blind, multicentre study evaluating the safety and efficacy of filgotinib and lanraplenib in patients with lupus membranous nephropathy. RMD Open 6, e001490 (2020).","journal-title":"RMD Open"},{"key":"1103_CR114","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1002\/art.42391","volume":"75","author":"E Morand","year":"2023","unstructured":"Morand, E. et al. Deucravacitinib, a tyrosine kinase 2 inhibitor, in systemic lupus erythematosus: a phase II, randomized, double-blind, placebo-controlled trial. Arthritis Rheumatol. 75, 242\u2013252 (2023).","journal-title":"Arthritis Rheumatol."},{"key":"1103_CR115","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT05620407 (2025)."},{"key":"1103_CR116","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT05617677 (2025)."},{"key":"1103_CR117","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1056\/NEJMoa2118025","volume":"387","author":"RA Furie","year":"2022","unstructured":"Furie, R. A. et al. Trial of anti-BDCA2 antibody litifilimab for systemic lupus erythematosus. N. Engl. J. Med. 387, 894\u2013904 (2022).","journal-title":"N. Engl. J. Med."},{"key":"1103_CR118","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1056\/NEJMoa2118024","volume":"387","author":"VP Werth","year":"2022","unstructured":"Werth, V. P. et al. Trial of anti-BDCA2 antibody litifilimab for cutaneous lupus erythematosus. N. Engl. J. Med. 387, 321\u2013331 (2022).","journal-title":"N. Engl. J. Med."},{"key":"1103_CR119","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1056\/NEJMoa2106535","volume":"386","author":"JT Merrill","year":"2022","unstructured":"Merrill, J. T. et al. Phase 2 trial of iberdomide in systemic lupus erythematosus. N. Engl. J. Med. 386, 1034\u20131045 (2022).","journal-title":"N. Engl. J. Med."},{"key":"1103_CR120","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1136\/annrheumdis-2022-222212","volume":"81","author":"PE Lipsky","year":"2022","unstructured":"Lipsky, P. E. et al. Biological impact of iberdomide in patients with active systemic lupus erythematosus. Ann. Rheum. Dis. 81, 1136\u20131142 (2022).","journal-title":"Ann. Rheum. Dis."},{"key":"1103_CR121","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2021-000581","volume":"9","author":"RA Furie","year":"2022","unstructured":"Furie, R. A. et al. Iberdomide in patients with systemic lupus erythematosus: a randomised double-blind, placebo-controlled, ascending-dose, phase 2a study. Lupus Sci. Med. 9, e000581 (2022).","journal-title":"Lupus Sci. Med."},{"key":"1103_CR122","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abf8442","volume":"13","author":"JL Karnell","year":"2021","unstructured":"Karnell, J. L. et al. Depleting plasmacytoid dendritic cells reduces local type I interferon responses and disease activity in patients with cutaneous lupus. Sci. Transl. Med. 13, eabf8442 (2021).","journal-title":"Sci. Transl. Med."},{"key":"1103_CR123","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/www.clinicaltrials.gov\/study\/NCT05540665 (2025)."},{"key":"1103_CR124","doi-asserted-by":"publisher","first-page":"91","DOI":"10.4049\/jimmunol.1501061","volume":"196","author":"M Sjostrand","year":"2016","unstructured":"Sjostrand, M. et al. The expression of BAFF is controlled by IRF transcription factors. J. Immunol. 196, 91\u201396 (2016).","journal-title":"J. Immunol."},{"key":"1103_CR125","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1002\/1529-0131(200106)44:6<1313::AID-ART223>3.0.CO;2-S","volume":"44","author":"GS Cheema","year":"2001","unstructured":"Cheema, G. S., Roschke, V., Hilbert, D. M. & Stohl, W. Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Arthritis Rheum. 44, 1313\u20131319 (2001).","journal-title":"Arthritis Rheum."},{"key":"1103_CR126","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1177\/0961203315604909","volume":"25","author":"DA Roth","year":"2016","unstructured":"Roth, D. A. et al. Elevated BLyS levels in patients with systemic lupus erythematosus: associated factors and responses to belimumab. Lupus 25, 346\u2013354 (2016).","journal-title":"Lupus"},{"key":"1103_CR127","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1002\/art.23678","volume":"58","author":"M Petri","year":"2008","unstructured":"Petri, M. et al. Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus. Arthritis Rheum. 58, 2453\u20132459 (2008).","journal-title":"Arthritis Rheum."},{"key":"1103_CR128","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/S0140-6736(10)61354-2","volume":"377","author":"SV Navarra","year":"2011","unstructured":"Navarra, S. V. et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 377, 721\u2013731 (2011).","journal-title":"Lancet"},{"key":"1103_CR129","doi-asserted-by":"publisher","first-page":"3918","DOI":"10.1002\/art.30613","volume":"63","author":"R Furie","year":"2011","unstructured":"Furie, R. et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 63, 3918\u20133930 (2011).","journal-title":"Arthritis Rheum."},{"key":"1103_CR130","doi-asserted-by":"publisher","first-page":"2733","DOI":"10.1093\/ndt\/gfad167","volume":"38","author":"HJ Anders","year":"2023","unstructured":"Anders, H. J. et al. Effect of belimumab on kidney-related outcomes in patients with lupus nephritis: post hoc subgroup analyses of the phase 3 BLISS-LN trial. Nephrol. Dial. Transplant. 38, 2733\u20132742 (2023).","journal-title":"Nephrol. Dial. Transplant."},{"key":"1103_CR131","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.kint.2021.08.027","volume":"101","author":"BH Rovin","year":"2022","unstructured":"Rovin, B. H. et al. A secondary analysis of the Belimumab International Study in Lupus Nephritis trial examined effects of belimumab on kidney outcomes and preservation of kidney function in patients with lupus nephritis. Kidney Int. 101, 403\u2013413 (2022).","journal-title":"Kidney Int."},{"key":"1103_CR132","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1016\/j.ekir.2023.06.021","volume":"8","author":"I Parodis","year":"2023","unstructured":"Parodis, I. et al. Effect of belimumab on preventing de novo renal lupus flares. Kidney Int. Rep. 8, 1822\u20131830 (2023).","journal-title":"Kidney Int. Rep."},{"key":"1103_CR133","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1136\/annrheumdis-2013-205144","volume":"74","author":"RA Furie","year":"2015","unstructured":"Furie, R. A. et al. A phase 2, randomised, placebo-controlled clinical trial of blisibimod, an inhibitor of B cell activating factor, in patients with moderate-to-severe systemic lupus erythematosus, the PEARL-SC study. Ann. Rheum. Dis. 74, 1667\u20131675 (2015).","journal-title":"Ann. Rheum. Dis."},{"key":"1103_CR134","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1136\/annrheumdis-2018-213032","volume":"77","author":"JT Merrill","year":"2018","unstructured":"Merrill, J. T. et al. Phase III trial results with blisibimod, a selective inhibitor of B-cell activating factor, in subjects with systemic lupus erythematosus (SLE): results from a randomised, double-blind, placebo-controlled trial. Ann. Rheum. Dis. 77, 883\u2013889 (2018).","journal-title":"Ann. Rheum. Dis."},{"key":"1103_CR135","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1517\/14712598.2016.1169270","volume":"16","author":"MA Scheinberg","year":"2016","unstructured":"Scheinberg, M. A., Hislop, C. M. & Martin, R. S. Blisibimod for treatment of systemic lupus erythematosus: with trials you become wiser. Expert Opin. Biol. Ther. 16, 723\u2013733 (2016).","journal-title":"Expert Opin. Biol. Ther."},{"key":"1103_CR136","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1136\/ard-2023-224854","volume":"83","author":"D Wu","year":"2024","unstructured":"Wu, D. et al. Telitacicept in patients with active systemic lupus erythematosus: results of a phase 2b, randomised, double-blind, placebo-controlled trial. Ann. Rheum. Dis. 83, 475\u2013487 (2024).","journal-title":"Ann. Rheum. Dis."},{"key":"1103_CR137","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1056\/NEJMoa2414719","volume":"393","author":"RF van Vollenhoven","year":"2025","unstructured":"van Vollenhoven, R. F. et al. A phase 3 trial of telitacicept for systemic lupus erythematosus. N. Engl. J. Med. 393, 1475\u20131485 (2025).","journal-title":"N. Engl. J. Med."},{"key":"1103_CR138","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT05339217 (2024)."},{"key":"1103_CR139","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT05306574 (2026)."},{"key":"1103_CR140","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT05687526 (2026)."},{"key":"1103_CR141","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1002\/art.40360","volume":"70","author":"JT Merrill","year":"2018","unstructured":"Merrill, J. T. et al. Efficacy and safety of atacicept in patients with systemic lupus erythematosus: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled, parallel-arm, phase IIb study. Arthritis Rheumatol. 70, 266\u2013276 (2018).","journal-title":"Arthritis Rheumatol."},{"key":"1103_CR142","doi-asserted-by":"publisher","DOI":"10.1186\/ar3738","volume":"14","author":"EM Ginzler","year":"2012","unstructured":"Ginzler, E. M. et al. Atacicept in combination with MMF and corticosteroids in lupus nephritis: results of a prematurely terminated trial. Arthritis Res. Ther. 14, R33 (2012).","journal-title":"Arthritis Res. Ther."},{"key":"1103_CR143","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT05639114 (2026)."},{"key":"1103_CR144","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT05624749 (2026)."},{"key":"1103_CR145","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT05126277 (2026)."},{"key":"1103_CR146","unstructured":"Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sj\u00f6gren\u2019s disease https:\/\/www.novartis.com\/news\/media-releases\/novartis-announces-both-ianalumab-phase-iii-clinical-trials-met-primary-endpoint-patients-sjogrens-disease (2025)"},{"key":"1103_CR147","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1016\/j.immuni.2020.11.006","volume":"53","author":"RA Elsner","year":"2020","unstructured":"Elsner, R. A. & Shlomchik, M. J. Germinal center and extrafollicular B cell responses in vaccination, immunity, and autoimmunity. Immunity 53, 1136\u20131150 (2020).","journal-title":"Immunity"},{"key":"1103_CR148","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1016\/j.immuni.2018.08.015","volume":"49","author":"SA Jenks","year":"2018","unstructured":"Jenks, S. A. et al. Distinct effector B cells induced by unregulated Toll-like receptor 7 contribute to pathogenic responses in systemic lupus erythematosus. Immunity 49, 725\u2013739.e6 (2018).","journal-title":"Immunity"},{"key":"1103_CR149","doi-asserted-by":"publisher","first-page":"6624","DOI":"10.4049\/jimmunol.178.10.6624","volume":"178","author":"C Wei","year":"2007","unstructured":"Wei, C. et al. A new population of cells lacking expression of CD27 represents a notable component of the B cell memory compartment in systemic lupus erythematosus. J. Immunol. 178, 6624\u20136633 (2007).","journal-title":"J. Immunol."},{"key":"1103_CR150","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.1002\/art.23498","volume":"58","author":"AM Jacobi","year":"2008","unstructured":"Jacobi, A. M. et al. Activated memory B cell subsets correlate with disease activity in systemic lupus erythematosus: delineation by expression of CD27, IgD, and CD95. Arthritis Rheum. 58, 1762\u20131773 (2008).","journal-title":"Arthritis Rheum."},{"key":"1103_CR151","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1111\/cei.13615","volume":"205","author":"Y Li","year":"2021","unstructured":"Li, Y., Li, Z. & Hu, F. Double-negative (DN) B cells: an under-recognized effector memory B cell subset in autoimmunity. Clin. Exp. Immunol. 205, 119\u2013127 (2021).","journal-title":"Clin. Exp. Immunol."},{"key":"1103_CR152","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1038\/ni.3175","volume":"16","author":"CM Tipton","year":"2015","unstructured":"Tipton, C. M. et al. Diversity, cellular origin and autoreactivity of antibody-secreting cell population expansions in acute systemic lupus erythematosus. Nat. Immunol. 16, 755\u2013765 (2015).","journal-title":"Nat. Immunol."},{"key":"1103_CR153","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-03750-7","volume":"9","author":"S Wang","year":"2018","unstructured":"Wang, S. et al. IL-21 drives expansion and plasma cell differentiation of autoreactive CD11chiT-bet+ B cells in SLE. Nat. Commun. 9, 1758 (2018).","journal-title":"Nat. Commun."},{"key":"1103_CR154","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1093\/rheumatology\/kex067","volume":"56","author":"V Reddy","year":"2017","unstructured":"Reddy, V. et al. Obinutuzumab induces superior B-cell cytotoxicity to rituximab in rheumatoid arthritis and systemic lupus erythematosus patient samples. Rheumatology 56, 1227\u20131237 (2017).","journal-title":"Rheumatology"},{"key":"1103_CR155","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1056\/NEJMoa2410965","volume":"392","author":"RA Furie","year":"2025","unstructured":"Furie, R. A. et al. Efficacy and safety of obinutuzumab in active lupus nephritis. N. Engl. J. Med. 392, 1471\u20131483 (2025).","journal-title":"N. Engl. J. Med."},{"key":"1103_CR156","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1002\/art.34359","volume":"64","author":"BH Rovin","year":"2012","unstructured":"Rovin, B. H. et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum. 64, 1215\u20131226 (2012).","journal-title":"Arthritis Rheum."},{"key":"1103_CR157","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1002\/art.27233","volume":"62","author":"JT Merrill","year":"2010","unstructured":"Merrill, J. T. et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II\/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum. 62, 222\u2013233 (2010).","journal-title":"Arthritis Rheum."},{"key":"1103_CR158","doi-asserted-by":"publisher","first-page":"2368","DOI":"10.1002\/art.38037","volume":"65","author":"EF Mysler","year":"2013","unstructured":"Mysler, E. F. et al. Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: results from a randomized, double-blind, phase III study. Arthritis Rheum. 65, 2368\u20132379 (2013).","journal-title":"Arthritis Rheum."},{"key":"1103_CR159","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1093\/rheumatology\/key042","volume":"57","author":"S Masoud","year":"2018","unstructured":"Masoud, S., McAdoo, S. P., Bedi, R., Cairns, T. D. & Lightstone, L. Ofatumumab for B cell depletion in patients with systemic lupus erythematosus who are allergic to rituximab. Rheumatology 57, 1156\u20131161 (2018).","journal-title":"Rheumatology"},{"key":"1103_CR160","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.2215\/CJN.01070118","volume":"13","author":"LM Gomez Mendez","year":"2018","unstructured":"Gomez Mendez, L. M. et al. Peripheral blood B cell depletion after rituximab and complete response in lupus nephritis. Clin. J. Am. Soc. Nephrol. 13, 1502\u20131509 (2018).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"1103_CR161","doi-asserted-by":"publisher","DOI":"10.1186\/ar3770","volume":"14","author":"YK Teng","year":"2012","unstructured":"Teng, Y. K. et al. Induction of long-term B-cell depletion in refractory rheumatoid arthritis patients preferentially affects autoreactive more than protective humoral immunity. Arthritis Res. Ther. 14, R57 (2012).","journal-title":"Arthritis Res. Ther."},{"key":"1103_CR162","doi-asserted-by":"publisher","first-page":"2672","DOI":"10.1002\/art.38074","volume":"65","author":"LM Carter","year":"2013","unstructured":"Carter, L. M., Isenberg, D. A. & Ehrenstein, M. R. Elevated serum BAFF levels are associated with rising anti-double-stranded DNA antibody levels and disease flare following B cell depletion therapy in systemic lupus erythematosus. Arthritis Rheum. 65, 2672\u20132679 (2013).","journal-title":"Arthritis Rheum."},{"key":"1103_CR163","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1038\/nrrheum.2016.18","volume":"12","author":"MR Ehrenstein","year":"2016","unstructured":"Ehrenstein, M. R. & Wing, C. The BAFFling effects of rituximab in lupus: danger ahead? Nat. Rev. Rheumatol. 12, 367\u2013372 (2016).","journal-title":"Nat. Rev. Rheumatol."},{"key":"1103_CR164","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1002\/art.41466","volume":"73","author":"Y Atisha-Fregoso","year":"2021","unstructured":"Atisha-Fregoso, Y. et al. Phase II randomized trial of rituximab plus cyclophosphamide followed by belimumab for the treatment of lupus nephritis. Arthritis Rheumatol. 73, 121\u2013131 (2021).","journal-title":"Arthritis Rheumatol."},{"key":"1103_CR165","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.7326\/M21-2078","volume":"174","author":"M Shipa","year":"2021","unstructured":"Shipa, M. et al. Effectiveness of belimumab after rituximabin systemic lupus erythematosus: a randomized controlled trial. Ann. Intern. Med. 174, 1647\u20131657 (2021).","journal-title":"Ann. Intern. Med."},{"key":"1103_CR166","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1093\/ndt\/gfaa117","volume":"36","author":"T Kraaij","year":"2021","unstructured":"Kraaij, T. et al. Long-term effects of combined B-cell immunomodulation with rituximab and belimumab in severe, refractory systemic lupus erythematosus: 2-year results. Nephrol. Dial. Transplant. 36, 1474\u20131483 (2021).","journal-title":"Nephrol. Dial. Transplant."},{"key":"1103_CR167","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2024-001424","volume":"12","author":"M van Schaik","year":"2025","unstructured":"van Schaik, M. et al. Long-term safety and efficacy of the combination of belimumab and rituximab in the treatment of severe and refractory SLE: a preliminary report. Lupus Sci. Med. 12, e001424 (2025).","journal-title":"Lupus Sci. Med."},{"key":"1103_CR168","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1136\/ard-2024-225686","volume":"83","author":"C Aranow","year":"2024","unstructured":"Aranow, C. et al. Efficacy and safety of sequential therapy with subcutaneous belimumab and one cycle of rituximab in patients with systemic lupus erythematosus: the phase 3, randomised, placebo-controlled BLISS-BELIEVE study. Ann. Rheum. Dis. 83, 1502\u20131512 (2024).","journal-title":"Ann. Rheum. Dis."},{"key":"1103_CR169","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-022-06874-w","volume":"23","author":"M van Schaik","year":"2022","unstructured":"van Schaik, M. et al. Efficacy of belimumab combined with rituximab in severe systemic lupus erythematosus: study protocol for the phase 3, multicenter, randomized, open-label Synbiose 2 trial. Trials 23, 939 (2022).","journal-title":"Trials"},{"key":"1103_CR170","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","volume":"28","author":"A Mackensen","year":"2022","unstructured":"Mackensen, A. et al. Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus. Nat. Med. 28, 2124\u20132132 (2022).","journal-title":"Nat. Med."},{"key":"1103_CR171","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1056\/NEJMoa2308917","volume":"390","author":"F Muller","year":"2024","unstructured":"Muller, F. et al. CD19 CAR T-cell therapy in autoimmune disease \u2014 a case series with follow-up. N. Engl. J. Med. 390, 687\u2013700 (2024).","journal-title":"N. Engl. J. Med."},{"key":"1103_CR172","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1056\/NEJMc2107725","volume":"385","author":"D Mougiakakos","year":"2021","unstructured":"Mougiakakos, D. et al. CD19-targeted CAR T cells in refractory systemic lupus erythematosus. N. Engl. J. Med. 385, 567\u2013569 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1103_CR173","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2025.152786","volume":"74","author":"A Nordmann-Gomes","year":"2025","unstructured":"Nordmann-Gomes, A. et al. CAR T-cell therapy in SLE: a systematic review. Semin. Arthritis Rheum. 74, 152786 (2025).","journal-title":"Semin. Arthritis Rheum."},{"key":"1103_CR174","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1136\/ard-2024-225785","volume":"83","author":"W Wang","year":"2024","unstructured":"Wang, W. et al. BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial. Ann. Rheum. Dis. 83, 1304\u20131314 (2024).","journal-title":"Ann. Rheum. Dis."},{"key":"1103_CR175","unstructured":"Yu, Y. et al. Allogenic CD19 CAR NK cells therapy in refractory systemic lupus erythematosus: an open-label, single arm, prospective and interventional clinical trial (abstract). Arthritis Rheumatol. https:\/\/acrabstracts.org\/abstract\/allogenic-cd19-car-nk-cells-therapy-in-refractory-systemic-lupus-erythematosus-an-open-label-single-arm-prospective-and-interventional-clinical-trial\/ (2024)."},{"key":"1103_CR176","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-46448-9","volume":"15","author":"M Doglio","year":"2024","unstructured":"Doglio, M. et al. Regulatory T cells expressing CD19-targeted chimeric antigen receptor restore homeostasis in systemic lupus erythematosus. Nat. Commun. 15, 2542 (2024).","journal-title":"Nat. Commun."},{"key":"1103_CR177","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1056\/NEJMc2509522","volume":"393","author":"Q Wang","year":"2025","unstructured":"Wang, Q. et al. In vivo CD19 CAR T-cell therapy for refractory systemic lupus erythematosus. N. Engl. J. Med. 393, 1542\u20131544 (2025).","journal-title":"N. Engl. J. Med."},{"key":"1103_CR178","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1056\/NEJMc2407150","volume":"391","author":"T Alexander","year":"2024","unstructured":"Alexander, T., Kronke, J., Cheng, Q., Keller, U. & Kronke, G. Teclistamab-induced remission in refractory systemic lupus erythematosus. N. Engl. J. Med. 391, 864\u2013866 (2024).","journal-title":"N. Engl. J. Med."},{"key":"1103_CR179","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT05085418 (2021)."},{"key":"1103_CR180","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT05938725?term=NCT05938725&rank=1 (2025)."},{"key":"1103_CR181","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1056\/NEJMoa2023325","volume":"383","author":"L Ostendorf","year":"2020","unstructured":"Ostendorf, L. et al. Targeting CD38 with daratumumab in refractory systemic lupus erythematosus. N. Engl. J. Med. 383, 1149\u20131155 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1103_CR182","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1038\/s41591-023-02479-1","volume":"29","author":"D Roccatello","year":"2023","unstructured":"Roccatello, D. et al. Daratumumab monotherapy for refractory lupus nephritis. Nat. Med. 29, 2041\u20132047 (2023).","journal-title":"Nat. Med."},{"key":"1103_CR183","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-026-69112-w","volume":"17","author":"L Ostendorf","year":"2026","unstructured":"Ostendorf, L. et al. Daratumumab in systemic lupus erythematosus: a single-arm phase 2 trial. Nat. Commun. 17, 1312 (2026).","journal-title":"Nat. Commun."},{"key":"1103_CR184","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT04868838 (2026)."},{"key":"1103_CR185","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1177\/0961203319896018","volume":"29","author":"A Segarra","year":"2020","unstructured":"Segarra, A. et al. Efficacy and safety of bortezomib in refractory lupus nephritis: a single-center experience. Lupus 29, 118\u2013125 (2020).","journal-title":"Lupus"},{"key":"1103_CR186","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2022.102870","volume":"132","author":"H Li","year":"2022","unstructured":"Li, H., Boulougoura, A., Endo, Y. & Tsokos, G. C. Abnormalities of T cells in systemic lupus erythematosus: new insights in pathogenesis and therapeutic strategies. J. Autoimmun. 132, 102870 (2022).","journal-title":"J. Autoimmun."},{"key":"1103_CR187","doi-asserted-by":"publisher","first-page":"2651","DOI":"10.4049\/jimmunol.130.6.2651","volume":"130","author":"M Linker-Israeli","year":"1983","unstructured":"Linker-Israeli, M. et al. Defective production of interleukin 1 and interleukin 2 in patients with systemic lupus erythematosus (SLE). J. Immunol. 130, 2651\u20132655 (1983).","journal-title":"J. Immunol."},{"key":"1103_CR188","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01536","volume":"9","author":"MM Xie","year":"2018","unstructured":"Xie, M. M. & Dent, A. L. Unexpected help: follicular regulatory T cells in the germinal center. Front. Immunol. 9, 1536 (2018).","journal-title":"Front. Immunol."},{"key":"1103_CR189","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1136\/ard-2022-222501","volume":"81","author":"JY Humrich","year":"2022","unstructured":"Humrich, J. Y. et al. Low-dose interleukin-2 therapy in active systemic lupus erythematosus (LUPIL-2): a multicentre, double-blind, randomised and placebo-controlled phase II trial. Ann. Rheum. Dis. 81, 1685\u20131694 (2022).","journal-title":"Ann. Rheum. Dis."},{"key":"1103_CR190","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT05262686 (2022)."},{"key":"1103_CR191","doi-asserted-by":"publisher","first-page":"3096","DOI":"10.1002\/art.38790","volume":"66","author":"AT Group","year":"2014","unstructured":"Group, A. T. Treatment of lupus nephritis with abatacept: the Abatacept and Cyclophosphamide Combination Efficacy and Safety Study. Arthritis Rheumatol. 66, 3096\u20133104 (2014).","journal-title":"Arthritis Rheumatol."},{"key":"1103_CR192","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1002\/art.38260","volume":"66","author":"R Furie","year":"2014","unstructured":"Furie, R. et al. Efficacy and safety of abatacept in lupus nephritis: a twelve-month, randomized, double-blind study. Arthritis Rheumatol. 66, 379\u2013389 (2014).","journal-title":"Arthritis Rheumatol."},{"key":"1103_CR193","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1002\/art.42557","volume":"75","author":"DR Jayne","year":"2023","unstructured":"Jayne, D. R. et al. Clinical and biomarker responses to BI 655064, an antagonistic anti-CD40 antibody, in patients with active lupus nephritis: a randomized, double-blind, placebo-controlled, phase II trial. Arthritis Rheumatol. 75, 1983\u20131993 (2023).","journal-title":"Arthritis Rheumatol."},{"key":"1103_CR194","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1177\/09612033251326990","volume":"34","author":"R Furie","year":"2025","unstructured":"Furie, R. et al. Two-year treatment experience with BI 655064, an antagonistic anti-CD40 antibody, in patients with active lupus nephritis: an exploratory, phase II maintenance trial. Lupus 34, 460\u2013473 (2025).","journal-title":"Lupus"},{"key":"1103_CR195","doi-asserted-by":"publisher","first-page":"5397","DOI":"10.1093\/rheumatology\/keab381","volume":"60","author":"RA Furie","year":"2021","unstructured":"Furie, R. A. et al. Phase 2, randomized, placebo-controlled trial of dapirolizumab pegol in patients with moderate-to-severe active systemic lupus erythematosus. Rheumatology 60, 5397\u20135407 (2021).","journal-title":"Rheumatology"},{"key":"1103_CR196","unstructured":"UCB and Biogen Announce Positive Topline Results From Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus and are Initiating Second Phase 3 Study in 2024, https:\/\/investors.biogen.com\/news-releases\/news-release-details\/dapirolizumab-pegol-phase-3-data-presented-american-college (2024)."},{"key":"1103_CR197","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00764","volume":"9","author":"KBM Reid","year":"2018","unstructured":"Reid, K. B. M. Complement component C1q: historical perspective of a functionally versatile, and structurally unusual, serum protein. Front. Immunol. 9, 764 (2018).","journal-title":"Front. Immunol."},{"key":"1103_CR198","doi-asserted-by":"publisher","first-page":"2677","DOI":"10.1002\/art.34473","volume":"64","author":"M Petri","year":"2012","unstructured":"Petri, M. et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 64, 2677\u20132686 (2012).","journal-title":"Arthritis Rheum."},{"key":"1103_CR199","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.1007\/s00296-024-05558-9","volume":"44","author":"J Smith","year":"2024","unstructured":"Smith, J., Hans, V., Yacyshyn, E., Rouhi, A. & Oliver, M. Systemic lupus erythematosus presenting with atypical hemolytic uremic syndrome: a case report and review of the literature. Rheumatol. Int. 44, 2213\u20132225 (2024).","journal-title":"Rheumatol. Int."},{"key":"1103_CR200","first-page":"2286","volume":"54","author":"MC Pickering","year":"2015","unstructured":"Pickering, M. C. et al. Eculizumab as rescue therapy in severe resistant lupus nephritis. Rheumatology 54, 2286\u20132288 (2015).","journal-title":"Rheumatology"},{"key":"1103_CR201","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT05268289 (2026)."},{"key":"1103_CR202","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1002\/art.30222","volume":"63","author":"H Sekine","year":"2011","unstructured":"Sekine, H. et al. The benefit of targeted and selective inhibition of the alternative complement pathway for modulating autoimmunity and renal disease in MRL\/lpr mice. Arthritis Rheum. 63, 1076\u20131085 (2011).","journal-title":"Arthritis Rheum."},{"key":"1103_CR203","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.1016\/j.ekir.2023.08.033","volume":"8","author":"BP Dixon","year":"2023","unstructured":"Dixon, B. P. et al. Clinical safety and efficacy of pegcetacoplan in a phase 2 study of patients with C3 glomerulopathy and other complement-mediated glomerular diseases. Kidney Int. Rep. 8, 2284\u20132293 (2023).","journal-title":"Kidney Int. Rep."},{"key":"1103_CR204","doi-asserted-by":"publisher","DOI":"10.2196\/81415","volume":"15","author":"DRW Jayne","year":"2026","unstructured":"Jayne, D. R. W. et al. Evaluation of the long-term safety of avacopan in antineutrophil cytoplasmic antibody-associated vasculitis in the real world (AvacoStar): protocol for a noninterventional prospective cohort study. JMIR Res. Protoc. 15, e81415 (2026).","journal-title":"JMIR Res. Protoc."},{"key":"1103_CR205","doi-asserted-by":"publisher","first-page":"23","DOI":"10.2147\/DDDT.S341842","volume":"19","author":"JR van Leeuwen","year":"2025","unstructured":"van Leeuwen, J. R. et al. Evaluating avacopan in the treatment of ANCA-associated vasculitis: design, development and positioning of therapy. Drug Des. Devel. Ther. 19, 23\u201337 (2025).","journal-title":"Drug Des. Devel. Ther."},{"key":"1103_CR206","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1038\/nm.4027","volume":"22","author":"C Lood","year":"2016","unstructured":"Lood, C. et al. Neutrophil extracellular traps enriched in oxidized mitochondrial DNA are interferogenic and contribute to lupus-like disease. Nat. Med. 22, 146\u2013153 (2016).","journal-title":"Nat. Med."},{"key":"1103_CR207","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1191\/096120399678847380","volume":"8","author":"JC Davis Jr.","year":"1999","unstructured":"Davis, J. C. Jr. et al. Recombinant human Dnase I (rhDNase) in patients with lupus nephritis. Lupus 8, 68\u201376 (1999).","journal-title":"Lupus"},{"key":"1103_CR208","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-025-00653-y","volume":"11","author":"I Parodis","year":"2025","unstructured":"Parodis, I. et al. Lupus nephritis. Nat. Rev. Dis. Primers 11, 69 (2025).","journal-title":"Nat. Rev. Dis. Primers"},{"key":"1103_CR209","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000007099","volume":"96","author":"J Narvaez","year":"2017","unstructured":"Narvaez, J. et al. The value of repeat biopsy in lupus nephritis flares. Medicine 96, e7099 (2017).","journal-title":"Medicine"},{"key":"1103_CR210","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfad063c_4570","volume":"38","author":"I Bajema","year":"2023","unstructured":"Bajema, I. et al. Relation of kidney biopsy findings to clinical outcomes in patients with lupus nephritis treated with an antagonistic anti-CD40 antibody (Bi 655064). Nephrol. Dial. Transplant. 38, gfad063c_4570 (2023).","journal-title":"Nephrol. Dial. Transplant."},{"key":"1103_CR211","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1136\/annrheumdis-2021-222069","volume":"81","author":"E Frangou","year":"2022","unstructured":"Frangou, E. et al. Cross-species transcriptome analysis for early detection and specific therapeutic targeting of human lupus nephritis. Ann. Rheum. Dis. 81, 1409\u20131419 (2022).","journal-title":"Ann. Rheum. Dis."},{"key":"1103_CR212","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1016\/j.ekir.2024.03.014","volume":"9","author":"I Parodis","year":"2024","unstructured":"Parodis, I. et al. Interferon and B-cell signatures inform precision medicine in lupus nephritis. Kidney Int. Rep. 9, 1817\u20131835 (2024).","journal-title":"Kidney Int. Rep."},{"key":"1103_CR213","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT04702256 (2025)."},{"key":"1103_CR214","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1177\/0961203318817132","volume":"28","author":"K Tselios","year":"2019","unstructured":"Tselios, K. et al. Disease course patterns in systemic lupus erythematosus. Lupus 28, 114\u2013122 (2019).","journal-title":"Lupus"},{"key":"1103_CR215","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1093\/rheumatology\/kez422","volume":"59","author":"M Zen","year":"2020","unstructured":"Zen, M. et al. Prevalence and predictors of flare after immunosuppressant discontinuation in patients with systemic lupus erythematosus in remission. Rheumatology 59, 1591\u20131598 (2020).","journal-title":"Rheumatology"},{"key":"1103_CR216","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1002\/acr.25611","volume":"78","author":"CK Cheung","year":"2026","unstructured":"Cheung, C. K. et al. Reduction in renal relapse and preservation of long-term kidney function after lupus low disease activity in patients with lupus nephritis. Arthritis Care Res. 78, 227\u2013236 (2026).","journal-title":"Arthritis Care Res."},{"key":"1103_CR217","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1177\/0961203312465781","volume":"22","author":"MA Dooley","year":"2013","unstructured":"Dooley, M. A. et al. Effect of belimumab treatment on renal outcomes: results from the phase 3 belimumab clinical trials in patients with SLE. Lupus 22, 63\u201372 (2013).","journal-title":"Lupus"},{"key":"1103_CR218","unstructured":"Di W. et al. Telitacicept, a human recombinant fusion protein targeting B lymphocyte stimulator (BlyS) and a proliferation-inducing ligand (APRIL), in systemic lupus erythematosus (SLE): results of a phase 3 study (abstract). Arthritis Rheumatol. https:\/\/acrabstracts.org\/abstract\/telitacicept-a-human-recombinant-fusion-protein-targeting-b-lymphocyte-stimulator-blys-and-a-proliferation-inducing-ligand-april-in-systemic-lupus-erythematosus-sle-results-of-a-phase-3-study\/ (2022)."},{"key":"1103_CR219","doi-asserted-by":"publisher","first-page":"2088","DOI":"10.4049\/jimmunol.177.4.2088","volume":"177","author":"B Berghofer","year":"2006","unstructured":"Berghofer, B. et al. TLR7 ligands induce higher IFN-alpha production in females. J. Immunol. 177, 2088\u20132096 (2006).","journal-title":"J. Immunol."},{"key":"1103_CR220","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1038\/nri.2016.90","volume":"16","author":"SL Klein","year":"2016","unstructured":"Klein, S. L. & Flanagan, K. L. Sex differences in immune responses. Nat. Rev. Immunol. 16, 626\u2013638 (2016).","journal-title":"Nat. Rev. Immunol."}],"container-title":["Nature Reviews Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41581-026-01103-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41581-026-01103-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41581-026-01103-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T12:02:50Z","timestamp":1789560170000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41581-026-01103-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,23]]},"references-count":220,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["1103"],"URL":"https:\/\/doi.org\/10.1038\/s41581-026-01103-y","relation":{},"ISSN":["1759-5061","1759-507X"],"issn-type":[{"value":"1759-5061","type":"print"},{"value":"1759-507X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,23]]},"assertion":[{"value":"2 July 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"L.A. has received grants from GSK and AstraZeneca and consulting fees for Alexion, Amgen, AstraZeneca, AbbVie, Alpine, Biogen, Bristol Myers Squibb, Boehringer Ingelheim, Chugai, GSK, Grifols, Janssen-Cilag, Kezar, LFB, Lilly, Medac, Novartis, Os\u00e9us, Pfizer, Roche, UCB, C\u00eamka, Ono Pharma and S\u00eameia; A.B. has received consultancy fees and honoraria from AstraZeneca, Bayer, Boehringer Ingelheim, Chemocentryx, CSL-Vifor, Fresenius, GSK, Sobi and Otsuka; F.C.F. has received fees from Novartis, Apellis, Alexion, SOBI, Bayer and AstraZeneca, outside the submitted work; G.M.F.J. has received honoraria for talks for GSK, Otsuka and Novartis and provided advisory work for Roche, GSK, Otsuka, SOBI and Vifor; J.F. has received lecture and\/or consultancy honoraria from AstraZeneca, Biogen, Boehringer, Calliditas, CSL-Vifor, Novartis, Omeros, Otsuka, Roche, Sobi, Stada, Travere, Tymberline, Vera-Therapeutics, Vertex and was involved in data safety monitoring boards for AstraZeneca, NovoNordisk, Visterra; A.M. has received consulting fees for lectures from BMS, GlaxoSmithKline, Novartis, Pfizer, Roche, Alexion, Astra Zeneca, Roche, Biogen; S.\u00a0Mirioglu has received support for meeting registration and travel from Amgen; I.P. has received research funding and\/or honoraria from Amgen, Argenx, AstraZeneca, Aurinia, Biogen, BMS, Elli Lilly, Gilead, GSK, Janssen, Novartis, Otsuka, Roche, UBC and Viatris; L.F.Q. has received consulting fees from Boehringer Ingelheim, CSL Vifor, GlaxoSmithKline, Novartis, Otsuka, Roche, Sobi, Alexion, Astra Zeneca; B.H.R. has received grants from the NIH, Lupus Research Association\u00a0and Biogen and served as a consultant\/advisor for Alexion, Aurinia, Argenx, Biogen, BMS, Calliditas, GSK, Travere, Genentech, Century, Novartis, AstraZeneca, Climb and Osuka; K.S. has received consulting fees from CSL Vifor; A.K. has received consulting fees from Amgen, Argenx, AstraZeneca, Boehringer Ingelheim, CSL, Delta4, GlaxoSmithKline, Novartis, Novo Nordisk, Otsuka, Roche, Sobi, Visterra, Walden Biosciences and serves as the editor-in-chief of Rare Kidney Diseases and an editor of\n                      Nephrology Dialysis Transplantation\n                      ; Y.K.O.T. has received research support from GlaxoSmithKline, Aurinia Pharmaceuticals and Vifor Pharma; E.F. has received support from AstraZeneca, Genesis, Novartis, Swixx BioPharma\u00a0and the State Health Services Organization of Cyprus and serves as an editor of\n                      Nephrology Dialysis Transplantation\n                      . The other authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}